- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03144817
Dialysate Sodium Lowering Trial (DeSaLT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- DCI Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18 years
- Patients undergoing thrice weekly in-center conventional HD
- At least 90 days since start of hemodialysis
- Absence of pulmonary edema / signs of fluid overload on physical exam
- Currently dialyzing at a DNa >=137 mEq/L
- Single session Kt/V >=1.3 each month for the past 2 months
- Hypertensive, defined by a pre-dialysis BP of >140/90 or treatment with 1 or more antihypertensive agents
- No more than 1 skipped treatment and no more than 1 session per month shortened by >10 min
- Life expectancy >12 months
- Able to provide Informed Consent
- Speaks and understands English
Exclusion Criteria:
- Prone to IDH, defined as IDH occurring in >10% of treatments in the past 3 months. IDH will be defined as symptoms (e.g. cramps, dizziness, loss of consciousness) and/or intra- or post-dialytic systolic BP <90 mm Hg and/or use of intervention(s) (UF goal lowered, treatment stopped early, or saline given) because of IDH
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
|
|
Experimental: Intervention Group
Intervention group will dialyze with dialysate Na 135 mEq/L.
|
Dialysate sodium is lowered until nadir sodium level is reached.
Participant dialyzes at this sodium level until end of follow-up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Intradialytic Hypotension
Time Frame: Baseline period through study completion, an average of 6 months
|
IDH is determined by review of blood pressures (measured every 30 minutes during dialysis), symptoms (recorded by the nurse during the dialysis treatment and reviewed at Q2 weekly face to face visits by the study team) and the need for intervention (targeted ultrafiltration goal was reduced; treatment was terminated early or saline given for intradialytic hypotension. IDH is defined by any 1 (or more of the following) 1) lowest intradialytic Systolic BP <90 mm Hg or 2) intradialytic symptoms (cramps, lightheadedness, nausea +/-vomiting, diaphoresis, loss of consciousness or seizure) OR 3) intervention performed for symptoms of IDH or lowest intradialytic BP <90 mm Hg. The # IDH events (meeting 1 or more of the 3 criteria above) per 100 treatments will be compared across treatment arms. |
Baseline period through study completion, an average of 6 months
|
Dialysis Dysequilibrium (Safety)
Time Frame: Baseline period through study completion, an average of 6 months
|
Ascertained via self-report on a questionnaire that asks about the frequency of symptoms suggestive of DD occurring during or immediately after dialysis.
The symptoms are: headache, nausea +/- vomiting, confusion, drowsiness, muscle twitching, blurred vision.
There are 5 response options ranging from never through to very often for each question.
The questionnaire is administered at baseline, at 6 weeks, and Q3 months thereafter.
The change in frequency of each symptom will be compared across arms.
|
Baseline period through study completion, an average of 6 months
|
Frequency of ER visits and hospitalizations (safety)
Time Frame: Baseline through study completion
|
The frequency of ER visits and hospitalizations will be ascertained at Q2 weekly study visits.
The # of events per time at risk will be compared across treatment arms.
|
Baseline through study completion
|
Frequency of patients treated to a dialysate Na 135 mEq/L at end of study (feasibility)
Time Frame: Last 2 weeks of Follow-up
|
Among those assigned to Dialysate Na 135 mEq/l as the denominator, the # actually continuing to dialyze at this level during the last two weeks of study follow-up.
|
Last 2 weeks of Follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre- and post-dialysis Plasma Sodium
Time Frame: Baseline period through study completion, an average of 6 months
|
Taken from lab draws immediately before and after start of dialysis treatment.
|
Baseline period through study completion, an average of 6 months
|
Dialysate Sodium
Time Frame: Baseline period through study completion, an average of 6 months
|
Sample of dialysate sodium taken 30 minutes after start of dialysis treatment.
|
Baseline period through study completion, an average of 6 months
|
Relative Blood Volume
Time Frame: Baseline period through study completion, an average of 6 months
|
Determined using CRIT LINE III monitors.
|
Baseline period through study completion, an average of 6 months
|
Bioimpedance Analysis
Time Frame: Baseline period through study completion, an average of 6 months
|
Water volume and bioimpedance results will be determined using InBodyS10 device.
|
Baseline period through study completion, an average of 6 months
|
Interdialytic Weight Gain
Time Frame: Baseline period through study completion, an average of 6 months
|
Determined by analysis of treatment sheets.
|
Baseline period through study completion, an average of 6 months
|
Post Dialysis Weight
Time Frame: Baseline period through study completion, an average of 6 months
|
Determined by analysis of treatment sheets.
|
Baseline period through study completion, an average of 6 months
|
Estimated Dry Weight
Time Frame: Baseline period through study completion, an average of 6 months
|
Determined by analysis of treatment sheets.
|
Baseline period through study completion, an average of 6 months
|
Pre- and Post-dialysis Sitting Blood Pressure
Time Frame: Baseline period through study completion, an average of 6 months
|
Determined by analysis of treatment sheets.
|
Baseline period through study completion, an average of 6 months
|
Home Blood Pressure Monitoring
Time Frame: Baseline period through study completion, an average of 6 months
|
Participants will use a LifeSource blood pressure monitor to measure their blood pressure weekly at home.
|
Baseline period through study completion, an average of 6 months
|
Sodium Loss during Dialysis
Time Frame: Baseline period through study completion, an average of 6 months
|
Calculated according to the formula: pre-dialysis total body Na - post-dialysis total body Na, where the volume of distribution in the extracellular space is estimated as 0.58*target weight.
|
Baseline period through study completion, an average of 6 months
|
Thirst and Xerostomia
Time Frame: Baseline through study completion, an average of 6 months
|
Thirst and Xerostomia will be measured via validated, self-administered questionnaires, the 'Dialysis Thirst Inventory' and the 'Xerostomia Inventory' , respectively (BotsCP et al, Kidney International:66; 2004). Change in each inventory score from baseline to the end of the study will be compared by treatment arm. |
Baseline through study completion, an average of 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dana Miskulin, MD, Tufts Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12393
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Dialysate Sodium Lowering
-
University Hospital, MontpellierRecruitingAcute Kidney Injury | Renal Replacement TherapyFrance
-
Lawson Health Research InstituteCompleted
-
Yale UniversitySatellite ResearchTerminatedHypertension | Hemodialysis PatientsUnited States
-
Yale UniversityTerminatedSafety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic HypotensionHemodialysis | HypotensionUnited States
-
Aristotle University Of ThessalonikiCompletedEnd Stage Kidney Disease | Intradialytic HypertensionGreece, Slovenia
-
University of SydneyPeking University People's Hospital; Institute for Clinical Evaluative Sciences and other collaboratorsRecruitingEnd-Stage Kidney DiseaseAustralia, Canada, United Kingdom, Malaysia, Germany, India
-
VA Office of Research and DevelopmentActive, not recruitingEnd-stage Renal DiseaseUnited States
-
Brigham and Women's HospitalCompletedIntra-dialytic HypotensionUnited States
-
National University Hospital, SingaporeNational University of SingaporeCompletedHypotension | Dialysis AmyloidosisSingapore
-
UPECLIN HC FM Botucatu UnespCompletedChronic Kidney Diseases Stage 5